Rating system for strength of recommendation and quality of evidence supporting the recommendation* |
Category Definition |
A Both strong evidence for efficacy and substantial clinical benefit support recommendation for use. Should always be offered. B Moderate evidence for efficacyor strong evidence for efficacy, but only limited clinical benefitsupports recommendation for use. Should generally be offered. C Evidence for efficacy is insufficient to support a recommendation for or against use, or evidence for efficacy may not outweigh adverse consequences (e.g., toxicity, drug interactions, or cost of the chemoprophylaxis or alternative approaches). Optional. D Moderate evidence for lack of efficacy or for adverse outcome supports a recommendation against use. Should generally not be offered. E Good evidence for lack of efficacy or for adverse outcome supports a recommendation against use. Should never be offered.
Categories Reflecting Quality of Evidence Supporting the Recommendation I Evidence from at least one properly randomized, controlled trial II Evidence from at least one well-designed clinical trial without randomization, from cohort or case-controlled analytic studies (preferably from more than one center), or from multiple time-series studies or dramatic results from uncontrolled experiments III Evidence from opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees *Modified from ( 5 ). |
Go to the USPHS/IDSA Guidelines Menu
Go to the Opportunistic Infections Menu
Go to the HIVpositive.us Main Menu